(Q24293022)

2

Noelyn M

Kljavin

1 reference

26 October 2023

Eric W Stawiski

3

Eric W

Stawiski

1 reference

26 October 2023

Emily Chan

4

Emily

Chan

1 reference

26 October 2023

Chaitali Parikh

5

Chaitali

Parikh

1 reference

26 October 2023

Steffen Durinck

6

Steffen

Durinck

1 reference

26 October 2023

Subhra Chaudhuri

7

Subhra

Chaudhuri

1 reference

26 October 2023

Kanan Pujara

8

Kanan

Pujara

1 reference

26 October 2023

Joseph Guillory

9

Joseph

Guillory

1 reference

26 October 2023

Kyle A Edgar

10

Kyle A

Edgar

1 reference

26 October 2023

Vasantharajan Janakiraman

11

Vasantharajan

Janakiraman

1 reference

26 October 2023

Rolf-Peter Scholz

12

Rolf-Peter

Scholz

1 reference

26 October 2023

Krista K Bowman

13

Krista K

Bowman

1 reference

26 October 2023

Maria Lorenzo

14

Maria

Lorenzo

1 reference

26 October 2023

Hong Li

15

Hong

Li

1 reference

26 October 2023

Jiansheng Wu

16

Jiansheng

Wu

1 reference

26 October 2023

Wenlin Yuan

17

Wenlin

Yuan

1 reference

26 October 2023

Zhengyan Kan

19

Zhengyan

Kan

1 reference

26 October 2023

Jeremy Stinson

20

Jeremy

Stinson

1 reference

26 October 2023

Ron Firestein

24

Ron

Firestein

1 reference

26 October 2023

Howard M Stern

25

Howard M

Stern

1 reference

26 October 2023

Krishnaraj Rajalingam

26

Krishnaraj

Rajalingam

1 reference

26 October 2023

Gabriele Schaefer

27

Gabriele

Schaefer

1 reference

26 October 2023

Mark X Sliwkowski

29

Mark X

Sliwkowski

1 reference

26 October 2023

Frederic J de Sauvage

30

Frederic J

de Sauvage

1 reference

26 October 2023

Somasekar Seshagiri

31

Somasekar

ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas

Seshagiri

1 reference

26 October 2023

language of work or name

English

0 references

publication date

13 May 2013

0 references

published in

Cancer Cell

0 references

volume

23

0 references

page(s)

603-17

0 references

issue

5

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

ErbB receptors and signaling pathways in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Cell signaling by receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

The upgraded role of HER3 and HER4 receptors in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

The ERBB3 receptor in cancer and cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Patterns of somatic mutation in human cancer genomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Somatic mutations affect key pathways in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Diverse somatic mutation patterns and pathway alterations in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Integrated genomic analyses of ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Systematic identification of genomic markers of drug sensitivity in cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

The landscape of cancer genes and mutational processes in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Comprehensive molecular characterization of human colon and rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Recurrent R-spondin fusions in colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Comprehensive molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Direct observation of individual endogenous protein complexes in situ by proximity ligation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Establishment of conditionally immortalized epithelial cell lines from both colon and small intestine of adult H-2Kb-tsA58 transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Ba/F3 cells and their use in kinase drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Structure of the extracellular region of HER3 reveals an interdomain tether

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

The mutational landscape of head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Synergy between Apc min and an activated ras mutation is sufficient to induce colon carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Structure-based view of epidermal growth factor receptor regulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

3D culture reveals a signaling network

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Emerging targeted therapies for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021

Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.04.012

7 January 2021